Monday, 14 June 2021

Recombinant Vaccines Market Growth, Trends and Value Chain 2020-2027

  Recombinant Vaccines Market Information: By Product (Subunit Recombinant and Attenuated Recombinant Vaccines), by Disease (Cancer, Pneumococcal Disease, Hepatitis B, and DPT), and End-Users (Pediatrics, Adults, and Veterinary) – Global Forecast Till 2027

Market Highlights

The recombinant vaccines market size is expected to exhibit a CAGR of 6.8% during the forecast period. Vaccines that are produced using recombinant DNA technology or genetic engineering are called recombinant vaccines. The recombinant vector vaccine strategy enables triggering of T- cells or B-cells thus generating a strong cell-mediated or humoral immune response in the body against that particular immunogen. The global recombinant vaccines market is majorly driven by increasing technical advanced research, increasing number of regulatory approvals, the high prevalence of infectious diseases and growing penetration of key market players. Furthermore, raising awareness of good health, favorable reimbursement policies, increasing innovations in research and development of drugs and vaccines as well as rising average income of individuals is propelling the market growth. However, factors such as high cost of vaccines, risks associated with live attenuated vaccines and stringent regulatory policies are likely to restrict the growth of the market. Lack of proper health care infrastructure, as well as awareness regarding opportunistic pathogen-related diseases in middle-income countries, are a major challenge to the market growth.

Get Sample Report at https://www.marketresearchfuture.com/sample_request/6130

Key Players:

Some of the key players in the Recombinant Vaccines Market Analysis are Abiomed, Emergent Bio Solutions, Inc., GlaxoSmithKline, Johnson & Johnson, Sanofi Pasteur SA, Serum Institute of India Pvt. Ltd, Mitsubishi Tanabe Pharma Corporation, Daiichi Sankyo, and Pfizer, Inc.

Segmentation

The global recombinant vaccines market is segmented on the basis of product type, diseases, and end-user. According to the product, the market is segmented into subunit recombinant vaccines, attenuated recombinant vaccines, and vector recombinant vaccines,

Considering the disease type, the market is segmented into pneumococcal disease, cancer, hepatitis B, influenza, DPT, and others.

On account of end-user, the market is segmented into hospitals & clinics, pediatrics, adults, veterinary, and others. Veterinary is further segmented to poultry and livestock.

Based on the region the market is segmented into Americas, Europe, Asia Pacific, and the Middle East and Africa. Americas region is segmented into North America and South America. Similarly, Europe is segmented into Western Europe and Eastern Europe.

Regional Analysis

Americas is the top market leader in the recombinant vaccines market owing to increasing advances in research in the field of molecular biology and genetic engineering as well as increasing prevalence of infectious diseases and cancer. Additionally, factors such as increasing government initiatives and funding for research, development of advanced medical treatment options, and rising demand for technologically advanced treatment are likely to enhance the growth of recombinant vaccines market in the American region. For instance, according to the stats presented by breast cancer organization about 12.4% of U.S. women are prone to develop invasive breast cancer over the course of her lifetime. Raising global burden of cancer has also led a lot of key players to invest their time and money to come up with solutions to curb this problem. For instance, the vaccine therapy with or without trastuzumab as well as GM-CSF vaccine for the treatment of breast cancer is in phases II clinical trial. Green signal from regulatory bodies for these vaccines will further boost up the market growth.

Europe is the second largest market and holds a healthy share in the global recombinant vaccines market due to major driving factors like availability of advanced treatment facilities, increasing healthcare expenditure along with the alarming rate of cancer and infectious diseases. Furthermore, Lots of established key players in this region export their products to the developing nation. For instance, the European Commission stated that the R&D spending by the pharmaceuticals and biotechnology sectors grew by 8.7% in 2014. This investment in R&D along with the ongoing legislative reforms is expected to have a positive impact on the recombinant vaccines market.

Asia Pacific is expected to be the fastest growing market owing to the faster adaptation of healthcare technology, increasing patient pool due to cancer and infectious diseases, government initiatives to increase the healthcare quality, favorable insurance, and reimbursement policies. Key players have set up their regional headquarters and manufacturing plants in Singapore, China, Japan, Korea, and Australia thus, boosting the growth of recombinant vaccines market. Government is also taking several initiatives to spread awareness in the low-income areas. As most of the developing country due to their poor hygienic conditions and large populations are more prone to infectious diseases, they have launched compulsory immunization program against influenza, DPT, measles, and Hepatitis B and C.

The Middle East & Africa is expected to show the least growth in the market due to some major factors such as lack of awareness, limited access and availability of treatment facilities. The Middle East has the largest market share owing to the development of healthcare industry and rising availability of specialty care centers in the United Arab Emirates and Saudi Arabia.

Access Report @ https://www.marketresearchfuture.com/reports/recombinant-vaccines-market-6130

About US:

Market Research Future (MRFR) enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact Us:

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune – 411028

Maharashtra, India

Phone: +1 646 845 9312

Email: sales@marketresearchfuture.com

 

Research report explores the Radiation Protection Apparels Market for the forecast period, 2020-2027

 It is estimated that the global Radiation Protection Apparels Market Share is expected to register a market value of USD 473 million in 2017, with a CAGR ~ 7.2% during the forecast period of 2018–2027.

Several factors such as increase in strict safety regulations by various government agencies such as Occupational Safety and Health Administration (OSHA), and National Institute for Occupational Safety and Health (NIOSH), and increase in the number of medical imaging processes are luring the growth of the market. However, high price of apparels, and detrimental effect of aprons on the health of the wearer are some of the factors curbing the growth of this market.

Get Sample Report at https://www.marketresearchfuture.com/sample_request/7451

The global radiation protection apparels market is currently dominated by many market players. The major players in the market are involved in new product launches and strategic collaborations to strengthen its market position. For instance, in May 2015, Ansell Limited acquired Microgard, a protective clothing manufacturer. With this acquisition, the company aims to increase its product portfolio and expand its geographical presence.

Key Players

Some of the key players in the global radiation protection apparels market are Kiran, Ultraray, Scanflex medical AB, MAVIG GmbH, Barrier Technologies, Biodex Medical Systems, Inc., CABLAS S.R.L, Lite Tech, Inc., Protech Medical, Rego X-ray GmbH, Shielding International, Inc., and Teijin Limited.

Segmentation

The global radiation protection apparels market has been segmented into product type, material, and end user.

The market, based on product type, has been segmented into aprons, gloves, head shields, thyroid shields, and others.

The market, by material, has been segmented into lead free, lead-based, light weight lead composite, and others.

The market, by end user has been segmented into hospitals and clinics, research laboratories, and others.

Regional Analysis

The market in the Americas is expected to dominate the global radiation protection apparels market during the forecast period owing to the presence of regulatory mandates. In addition, proactive government initiatives to spread awareness about the benefits of radiation protection apparel among the masses have supplemented the market growth. Europe is expected to hold the second largest position in the global radiation protection apparels market. The market growth in this region is because of the presence of a well-established healthcare system and increase in reimbursement policies. Asia-Pacific is estimated to be the fastest growing region in the market due to the improved healthcare infrastructure in the region. The market in the Middle East & Africa is likely to account for the smallest share of the global radiation protection apparels market.

Browse Complete Report @ https://www.marketresearchfuture.com/reports/radiation-protection-apparels-market-7451

Porcine Vaccines Market Size, Share, Demand, Financial Overview, Key Developments, Swot Analysis and Forecast to 2027

 Segmentation

 The global porcine vaccines market has been segmented into type, disease indication, and end user.

 By type, the market has been segmented into Inactivated vaccines, Live attenuated vaccines, Toxoid vaccines, Recombinant vaccines, Conjugate vaccines, DNA vaccines.

 On the basis of disease indication, the global porcine vaccines market has been segmented into PED (Porcine Epidemic Diarrhea), PRRS (Porcine Reproductive & Respiratory Syndrome), Swine influenza, Aujeszky's disease (AD), Porcine Circovirus Associated Disease (PCVAD) and others.

 The global porcine vaccines market, by end user, has been segmented into Veterinary Hospitals and Hog Production Farm.

 Get Sample Report at https://www.marketresearchfuture.com/sample_request/7438

 Market Highlights

 The global Porcine Vaccines Market Trends held a market value of USD 1910.7 million in 2017 and is projected to grow at a CAGR of 7.1% over the forecast period. Porcine vaccines aid the swine or hogs suffering from epidemic swine diseases. It also helps in improving overall efficiency in protecting swine from deadly viruses, bacteria and increases the production level of high-quality meat and gelatine. The increasing prevalence of swine diseases such as PED (Porcine Epidemic Diarrhea), PRRS (Porcine Reproductive & Respiratory Syndrome), swine influenza etc. are anticipated to drive the market growth during the forecast period.  Additionally, rising number of biotechnology companies, research institutions engaged in research and development of porcine vaccines, and government initiatives for funding agriculture and animal husbandry sector and increasing demand for porcine meat and gelatine are likely to contribute to the market growth. For instance, by the world by per-capita pig meat consumption, US has an average of 64.4 kilos of meat consumed in 2017. According to National Pork Producers Council the pork production has an estimated USD 23.4 billion of gross output nationwide. However, high cost of maintaining vaccines may hamper the market growth during the assessment period.

 Key Players

 Some of the prominent players in the global porcine vaccines market are Bayer AG, Bimeda, Inc., Boehringer Ingelheim International GmbH, Ceva Sante Animale, Eli Lilly and Company, Merck & Co., Inc., Sanofi S.A., Vetoquinol S.A., Zoetis, Inc., PBS Animal Health, Aptimmune.

 Regional Analysis

 On regional basis, the Americas is anticipated to dominate the global porcine vaccines market owing to the increasing prevalence of porcine diseases such as PED (Porcine Epidemic Diarrhea), PRRS (Porcine Reproductive & Respiratory Syndrome), swine influenza etc. and rapid increase in pig farms.  Additionally, rise in number of contract farming and independent farming for pig cultivation is contributing the market growth. According to The United States Department of Agriculture, National Agricultural Statistics Service “Livestock Slaughter” report, U.S. pork production was around 2 billion pound in 2016. Europe is expected to hold the second largest position in the global porcine vaccines market owing to increasing number of production units for pigs and high consumption of pork meat. The Asia-Pacific region is anticipated to be fastest growing region is due to introduction of new vaccines, initiatives by various government agencies, animal care associations, and incidence of major key players for growth and development in this region. The Middle East & Africa has the least share of the global porcine vaccines market. Moreover, the major market share of the region is expected to be held by the Middle East region owing to the increasing government initiatives for the agriculture and animal husbandry sector. 

Browse Complete Report @ https://www.marketresearchfuture.com/reports/porcine-vaccines-market-7438

3D Bioprinting Market Size, Share, Demand, Financial Overview, Key Developments, Swot Analysis and Forecast to 2027

 The global 3D Bioprinting Market Share is projected to touch USD 1,923.02 million by 2027, asserts Market Research Future (MRFR). The market can showcase an impressive 24.59% CAGR from 2018 to 2027 (forecast period) to reach this value. It was previously valued at USD 517.97 million in 2017.

Increasing demand for organ transplantation is projected to drive market demand year-on-year till 2027. This is attributed to the paucity of organs available for transplants. In 2014, nearly 120,000 people were on the waiting list for organs. This opportunity can be capitalized by the 3D bioprinting market by manufacturing customized organs according to body size.

Get Sample Report at https://www.marketresearchfuture.com/sample_request/869

Investments in 3D bioprinting via public and private means to widen its scope is likely to boost the market growth. For instance, Tekes, the Finnish Funding Agency for Innovation, awarded funds to the University of East Finland to develop a fully functioning 3D brain for research purposes. Moreover, cost-efficiency of 3D bioprinted products is likely to lead to renewed interest by investors.

Lack of awareness of the technology and shortage of skilled professionals can act as growth deterrents in the market.

Competitive Analysis:

Prominent names in the 3D Bioprinting Market are Nano3D Biosciences Inc. (U.S.), REGENHU Ltd. (Switzerland), FUJIFILM Wako Automation Corporation (U.S.), Allevi (U.S.), Organovo Holdings Inc. (U.S.), Regenovo Biotechnology Co. Ltd. (China), Aspect Biosystems Ltd. (Canada), Stratasys Ltd. (U.S.), Poietis (France), Cellink AB (Sweden), EnvisionTEC GmbH (Germany), and Cyfuse Biomedical K.K. (Japan).

Segmentation Analysis:

The 3D bioprinting market is segmented by technology, material, application, and end-user.

By technology, microextrusion bioprinting held close to 31.7% share in 2017, followed by inkjet 3D bioprinting (25.1%), laser-assisted bioprinting (20.6%), magnetic 3D bioprinting (13.7%), and others (8.9%). The microextrusion bioprinting segment is projected to register a whopping 25.24% CAGR during the forecast period. This can be attributed to its extensive applications in bioprinting. On the other hand, inkjet 3D bioprinting can exhibit 26.44% CAGR owing to being a viable alternative for scaffold fabrication.

By material, living cells accounted for 39.7% share in 2017, followed by hydrogels (30.8%), extracellular matrices (21.0%), and others (8.5%). Living cells are predicted to exhibit 25.05% CAGR during the forecast period thanks to the expedited production process of micro building blocks. The blocks play a vital role in repairing damaged tissues. Hydrogels, on the other hand, can generate close to USD 652.54 million by 2027 at a CAGR of 26.63% during the forecast period.

Among applications, research applications accounted for 73% share in 2017, followed by clinical applications with 27% share in the same year. Research applications can exhibit 24.74% CAGR till 2027 owing to applications in 3D cell culture and regenerative medicine. Clinical applications, on the other hand, can generate close to USD 507.55 million by 2027, at a 24.19% CAGR during the assessment period.

Among end-users, pharmaceutical & biotechnology companies accounted for 52.6% share in 2017, followed by research organizations & academic institutes (33.3%), and others (14.1%). Pharmaceutical & biotechnology companies are projected to display 24.98% CAGR till 2027 owing to the trend in personalized medicines.

Regional Analysis:

Region-wise, the 3D bioprinting market is segmented into Europe, Americas, Asia Pacific (APAC), and the Middle East & Africa (MEA). Americas held close to 38.1% market share in 2017, followed by Europe (31.8%), APAC (23.2%), and MEA (6.9%).

The Americas region is touted to touch a valuation of USD 689.91 million by 2027. This can be attributed to investments in research and development, presence of developed healthcare infrastructure, and massive demand for organs among the patient pool. Furthermore, development of 3D printed pills which can be customized according to person age and body weight is likely to open up growth opportunities for the 3D bioprinting market to expand in the region.

The APAC region can grow at a rapid pace owing to developments in the healthcare sector, development in 3D printing, and abundance of opportunities. The region can garner close to USD 507.18 million by 2027 at a CAGR of 27.25% during the forecast period. In addition, government funding to accelerate the pace of 3D printing technology can bode well for the market.

The Europe 3D bioprinting market can touch a value of USD 649.91 million by 2027 owing to increased focus on health and wellness. Rise in cosmetic surgery demand is likely to play a huge role for the market’s progress in the region. Agreements between prime players to expedite the evolution of the technology can net novel results. This is exemplified by the deal signed between BASF SE and Poietis to improve skin care products by the former.

Browse Full Report @ https://www.marketresearchfuture.com/reports/3d-bioprinting-market-869

Orthodontic Supplies Market Growth, Trends and Value Chain 2020-2027

 The global Orthodontic Supplies Market Size is expected to grow at an approximate CAGR of 8.75% during forecast period, 2018–2027.

Rising popularity of dental tourism is the key factor driving the orthodontic supplies market. For instance, in 2018, Ormco Corporation introduced a new line of premium orthodontic instruments to assist specialists with all dental procedures.

Get Sample Report at https://www.marketresearchfuture.com/sample_request/7364

Various other factors such as favorable reimbursement for dental procedures, high prevalence of orthodontic conditions, technological advancements, and increasing disposable incomes are also expected to propel the growth of the market.

However, the risks associated with orthodontic treatments, and high cost of advanced orthodontic treatments in some countries can hinder the market growth over the forecast period.

Key Players

Some of the key players in the global Orthodontic Supplies Market are 3M, Align Technology, American Orthodontics, Danaher, DB Orthodontics, Dental Morelli, Dentaurum, Dentsply Sirona, G&H Orthodontics, Great Lakes Orthodontics, Henry Schein, Rocky Mountain Orthodontics, Straumann Holding AG, TP Orthodontics, Ultradent Products, and others.

Segmentation

The global orthodontic supplies market is segmented based on product, patient, end user, and region.

The global market for orthodontic supplies, by product is segmented into fixed braces, removable braces, adhesives, and accessories.The fixed braces segment is further classified as brackets, archwires, anchorage appliances, and ligatures. The brackets segment includes conventional brackets, self-ligating brackets, and lingual brackets. The archwires segment includes beta titanium archwires, nickel titanium archwires, and stainless steel archwires. The anchorage appliances segment includes bands and buccal tubes, and miniscrews. The ligatures segment includes elastomeric ligatures, and wire ligatures.

Based on patient type, the market is segmented into children and teenagers, and adults.

Based on end user, the market is segmented into hospitals, clinics, and others. The hospitals segment is anticipated to hold the largest market share owing to the increasing cases of orthodontic conditions.

Regional Analysis

The Americas dominated the global market for orthodontic supplies owing to the presence of major market players, and improvement in the reimbursement scenario within the region.

In 2017, it was estimated that Europe stood second in the global orthodontic supplies market. This can be attributed to the increasing technological advancements, and rising research and development investments.

Asia Pacific was projected to be the fastest growing region in 2017. Increasing awareness about dental tourism drives the regional markets of the Asia Pacific region. Due to low prices for dental care, Thailand is becoming a trending location for dental tourism among the international dental tourists. For instance, dental veneers can cost around USD 1800 in the US with the same procedure costing about USD 250 in Thailand.

On the other hand, the Middle East and Africa held least share in the global orthodontic supplies market due to the low economic development, especially within the African region.

Get Full Report at https://www.marketresearchfuture.com/reports/orthodontic-supplies-market-7364

Sexual Wellness Market to Witness Widespread Expansion During 2020-2027

 Market Highlights

The global sexual wellness anticipated to have held a market value of USD 21.26 billion in the year 2017 and is expected to grow at a CAGR of 9.2% during the forecast period. Sexual health is experience of physical, psychological and social cultural related to sexuality. The products such as, sex toys, condom & contraceptives, sexual enhancement supplements, lubricants, ointments view as a sexual wellness product that provides enjoyment in sexual experience and security.

Get Sample Report at https://www.marketresearchfuture.com/sample_request/7328

Increasing global prevalence of Sexually Transmitted Diseases (STDs), increase in awareness regarding sexual health items, and development of e-commerce business are expected to drive the growth of market. According to the Centers for Disease Control and Prevention (CDC), in 2017 around 1,708,569 were suffer with Chlamydia trachomatis infection in US. Similarly, in 2017, around 555,608 were suffer with gonorrhea and 30,644 were suffer with Syphilis in US. Moreover, According to World Health Organization (WHO), every year estimated around 357 million new people suffer with sexually transmitted infections (STIs). Furthermore, according to The Joint United Nations Programme on HIV/AIDS (UNAIDS), in 2017 estimated that 5.2 million suffer with HIV in Asia-Pacific. On other hand, side effects due to toxic ingredients in products and product recalls can restrain the market growth over the assessment period.

Key Players

Some of the prominent players in the global Sexual Wellness Market Growth are LELO (Sweden), Doc Johnson (US), Church & Dwight Co., Inc. (US), Ansell Ltd. (Australia), Reckitt Benckiser Group plc (UK), LifeStyles Healthcare (Australia), Karex Berhad (Malaysia), Veru Inc. (US), Mankind Pharma (India), and BioFilm IP LLC (US).

 

Segmentation

The global Sexual Wellness Market Growth has been segmented into product and distribution channels.

Based on product, sexual wellness market is segmented into sex toys, condom & contraceptives, sexual enhancement supplements, lubricants, ointments, and others. The sex toys segment is expected to account for the largest share segment of the market in 2017.

Based on distribution channels, sexual wellness market is segmented into retail and online platforms. The retail segment is expected to account for the largest share segment of the market in 2017. Retail segment further sub segmented into drug stores, specialty stores, and others.

Regional Analysis

Geographically, the Americas is expected to dominate the global sexual wellness market owing to the presence of well-established players, increasing prevalence of Sexually Transmitted Diseases (STDs), increase in awareness regarding sexual health items, and developed e-commerce business. Europe is expected to hold the second largest position in the global sexual wellness market. Asia-Pacific is expected to be the fastest growing market owing to the increasing awareness about sexual wellness products and supportive sex education programs. Furthermore, the Middle East and Africa region is expected to account for the least market share in the global sexual wellness market.

Browse Complete Report @ https://www.marketresearchfuture.com/reports/sexual-wellness-market-7328

Wednesday, 9 June 2021

Dravet syndrome Market size in terms of volume and value 2020-2027

 Market Scenario:

Dravet syndrome is a rare genetic epileptic encephalopathy that begins during the first year of life in an otherwise healthy infant. According to the National Center for Advancing Translational Sciences, in 15% to 25% cases of the Dravet syndrome, a family history of epilepsy or febrile seizures exists. It is also reported that 85% cases of Dravet syndrome originated due to a mutation in the SCN1A gene.

It is noted that development of new drugs and therapies, and rising R&D expenditure are propelling the growth of the market. In recent years, Dravet syndrome has gained significant attention due to the upcoming drugs for its treatment. For instance, on February 06, 2018, Zogenix, Inc. received breakthrough therapy designation from FDA for its product, ZX008. The drug is specialized for the treatment of Dravet syndrome and its related complications.

Get Sample Copy @ https://www.marketresearchfuture.com/sample_request/5509

Various other factors such as unmet medical needs, increasing government assistance, rising healthcare expenditure in the developed countries, improving regulatory framework, increasing adoption rate, and rising funding and reimbursement policies are continuously contributing to the growth of the global Dravet syndrome market.

Despite these drivers, there are some issues associated with Dravet syndrome market. The side effects of drugs and other therapeutic agents, lack of awareness in the developing countries, and poor healthcare system in low and middle-income countries, may hinder the growth of the market.

It is estimated that the Dravet syndrome market is expected to grow at a CAGR of 8.5% during the forecast period of 2017-2023.

Intended Audience:

  • Pharmaceutical Companies
  • Research and Development (R&D) Companies
  • Government Research Institute
  • Academic Institutes and Universities

Key Players:

Some of key the players in the global dravet syndrome market are Biocodex, Biscayne Neurotherapeutics, Cyberonics, Inc., Epygenix Therapeutics, Inc., GW Pharmaceuticals, plc, INSYS THERAPEUTICS, INC., OPKO Health Inc., Ovid Therapeutics, PTC Therapeutics, Sage Therapeutics, Takeda Pharmaceutical Company Limited, Thermo Fisher Life Technologies, Xenon Pharmaceuticals, Zogenix, Inc, and others.

Segmentation:

The global Dravet syndrome market is segmented on the basis of the type of seizures, diagnosis, treatment & management, and end-user.

On the basis of the type of seizures, the market is classified as myoclonic seizures, atonic seizures, partial seizures, absence seizures, tonic clonic seizures, photosensitive seizures, and others.

On the basis of the diagnosis, the market is classified as magnetic resonance imaging (MRI), electroencephalography (EEG), SCN1A testing, and others.

On the basis of the treatment & management, the market is classified as seizure medications, ketogenic diet, vagus nerve stimulation (VNS), and others. The seizure medications segment is further classified into clobazam, stiripentol, sodium valproate, and others.

On the basis of the end-user, the market is segmented into pharmaceutical companies, hospitals, diagnostic laboratories, academic and research institutes, and others.

Browse More Details of the Report @  https://www.marketresearchfuture.com/reports/dravet-syndrome-market-5509

 

About US:

Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact Us:

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune – 411028

Maharashtra, India

Phone: +1 646 845 9312

Email: sales@marketresearchfuture.com